Beat AML 1.0 is a collaborative research program involving 11 academic medical centers who worked collectively to better understand drugs and drug combinations that should be prioritized for further development within clinical and/or molecular subsets of acute myeloid leukemia (AML) patients. Beat AML 1.0 provides the largest-to-date dataset on primary acute myeloid leukemia samples offering genomic, clinical, and drug response.This dataset contains open Clinical Supplement and RNA-Seq Gene Expression Quantification data.This dataset also contains controlled Whole Exome Sequencing (WXS) and RNA-Seq Aligned Reads, WXS Annotated Somatic Mutation, WXS Raw Somatic Mutation, and RNA-Seq Splice Junction Quantification
Genomic Data Commons (GDC) is source of truth for this dataset; GDC offers monthly data releases, although this dataset may not be updated at every release.
NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies
See all datasets managed by Center for Translational Data Science at The University of Chicago.
Beat Acute Myeloid Leukemia (AML) 1.0 was accessed on
DATE from https://registry.opendata.aws/beataml.
aws s3 ls --no-sign-request s3://gdc-beataml1-cohort-phs001657-2-open/
aws s3 ls --no-sign-request s3://gdc-beataml1.0-crenolanib-phs001628-2-open/